<SEC-DOCUMENT>0001299130-20-000010.txt : 20200306
<SEC-HEADER>0001299130-20-000010.hdr.sgml : 20200306
<ACCEPTANCE-DATETIME>20200305180556
ACCESSION NUMBER:		0001299130-20-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200305
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200306
DATE AS OF CHANGE:		20200305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		20691990

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pacb-20200305x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.36.2.2-->
<!--Created on: 3/5/2020 3:57:33 PM-->
<html>
	<head>
		<title>
			20200306 8-K
		</title>
	</head>
	<body><div style="margin-left:54pt;margin-right:54pt;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:4pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 18pt">
			<a name="_GoBack"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:18pt;">UNITED STATES </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 18pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:18pt;">SECURITIES AND EXCHANGE COMMISSION </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">Washington, DC 20549 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 18pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:18pt;">FORM 8-K </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 14pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:14pt;">CURRENT REPORT </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">Pursuant to Section 13 or 15(d) of </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">The Securities Exchange Act of 1934 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">Date of Report (Date of earliest event reported) </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">March </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">2</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">2020</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 24pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:24pt;">Pacific Biosciences of California, Inc. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">(Exact name of registrant as specified in its charter) </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">001-34899</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">16-1590339</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(State or other jurisdiction</font></p>
					<p style="margin:0pt 0pt 1pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">of incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(Commission</font></p>
					<p style="margin:0pt 0pt 1pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">File Number)</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(IRS Employer</font></p>
					<p style="margin:0pt 0pt 1pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">1305 O&#x2019;Brien Drive </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Menlo Park, California 94025 </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(Address of principal executive offices) (Zip Code) </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">(650) 521-8000 </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(Registrant&#x2019;s telephone number, including area code) </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">(Former name or former address, if changed since last report) </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:3pt;">
			<tr>
				<td valign="middle" style="width:17.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:21.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:464.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:18.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:23.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:462.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:17.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:21.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:464.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:17.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:21.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:464.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act: </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Trading Symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:171.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Common Stock, par value $0.001 per share</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">PACB</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:160.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">The NASDAQ Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xA7;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xA7;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">240.12b-2 of this chapter). </font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Emerging growth company </font><font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="display: inline;font-family:Segoe UI Symbol;color:#000000;font-size:10pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;color:#000000;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:3pt;">
			<tr>
				<td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:457.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">ITEM 5.02.</font></p>
				</td>
				<td valign="top" style="width:457.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In conjunction with its annual review of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">leadership structure</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of the board of directors (the &#x201C;Board&#x201D;) of Pacific Biosciences of California, Inc. (the &#x201C;Company&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and in keeping with good governance practices, the Board has decided to separate the Chair and Chief Executive Officer positions.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">On </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">March </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2020</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Board </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">appointed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Christian </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">O. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Henry</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as Chairman</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of the Board, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">effective immediately</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Michael Hunkapiller w</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ill continue to serve as a member of the Board and the President and Chief Executive of the Company. </font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In connection with Mr. Henry&#x2019;s appointment as Chairman of the Board, Mr. Henry</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;w</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ill </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">receive an additional annual retainer of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">35</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as well as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a stock option to purchase 35,000 shares of the Company&#x2019;s common stock</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">light of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the appointment of a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">independent </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Chairman, the Board eliminated the position of Lead Independent Director. As a result, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">William Ericson w</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ill no longer </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">serve as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company&#x2019;s </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Lead Independent Director</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">but will continue to serve as a member of the Board</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Chair of the Compensation Committee of the Board and member of the Nominating and Corporate Governance Committee of the Board</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;">Item 9.01.</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;">FINANCIAL STATEMENTS AND EXHIBITS. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;background-color: #FFFFFF;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;background-color: #FFFFFF;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(d) Exhibits</font>
		</p>
		<p style="margin:0pt 0pt 6pt;background-color: #FFFFFF;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Exhibit No. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Description</font>
		</p>
		<p style="margin:0pt 0pt 6pt 72pt;background-color: #FFFFFF;line-height:100%;text-indent: -72pt;font-family:Calibri;font-size: 10pt">
			<a href="pacb-20200305xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">99.1</font></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 60pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"></font><a href="pacb-20200305xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Press Release dated March 5, 2020 titled &#x201C;Christian Henry Appointed Chairman of Pacific Biosciences&#x2019; Board of Directors&#x201D;</font></a>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;color:#000000;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">SIGNATURE </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="right" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:181.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:206.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Pacific Biosciences of California, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:18.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:12.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:187.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:12.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:18.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">By:</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:181.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Susan K. Barnes </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:18.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:06.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:181.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Susan K. Barnes</font></p>
					<p style="margin:0pt 0pt 1pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:8pt;">Executive Vice President, Chief Financial Officer &amp; Principal Accounting Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Date: </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">March </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2020</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pacb-20200305xex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.36.2.2-->
<!--Created on: 3/5/2020 3:57:42 PM-->
<html>
	<head>
		<title>
			Exhibit 991
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;font-weight:bold;">Exhibit 99.1</font>

		</p>

</div>
		<p style="margin:0pt 9pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<a name="_GoBack"></a><font style="display: inline;color:#2B579A;background-color: #E6E6E6;"><img src="pacb-20200305xex99_1g001.jpg" style="width: 2.978472in; height: 0.6951389in" alt="image"></font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Christian Henry </font><font style="display: inline;font-weight:bold;">Appointed</font><font style="display: inline;font-weight:bold;"> Chairman of </font><font style="display: inline;font-weight:bold;">Pacific Biosciences&#x2019;</font><font style="display: inline;font-weight:bold;"> Board of Directors</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">MENLO PARK, Calif., March </font><font style="display: inline;font-weight:bold;">5</font><font style="display: inline;font-weight:bold;">, &nbsp;</font><font style="display: inline;font-weight:bold;">2020</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&#x2013;</font><font style="display: inline;"> Pacific Biosciences of California, Inc. (Nasdaq:PACB), </font><font style="display: inline;">a</font><font style="display: inline;"> leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry </font><font style="display: inline;">has</font><font style="display: inline;"> been</font><font style="display: inline;"> appointed </font><font style="display: inline;">to </font><font style="display: inline;">serve as Chairman of </font><font style="display: inline;">its Board of Directors. </font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;line-height:107.92%;font-size: 12pt">
			<font style="display: inline;font-family:Times;">As part of</font><font style="display: inline;font-family:Times;"> its annual review of the leadership structure of</font><font style="display: inline;font-family:Times;">&nbsp;</font><font style="display: inline;font-family:Times;">Pacific Biosciences</font><font style="display: inline;font-family:Times;">, &nbsp;</font><font style="display: inline;font-family:Times;">the</font><font style="display: inline;font-family:Times;"> Board of Directors </font><font style="display: inline;font-family:Times;"> decided to separate the Chair</font><font style="display: inline;font-family:Times;">man</font><font style="display: inline;font-family:Times;"> and Chief Executive Officer positions</font><font style="display: inline;font-family:Times;"> in alignment with best practices</font><font style="display: inline;font-family:Times;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;line-height:107.92%;font-size: 12pt">
			<font style="display: inline;font-family:Times;">Mr</font><font style="display: inline;font-family:Times;">. Henry </font><font style="display: inline;font-family:Times;">will become</font><font style="display: inline;font-family:Times;"> Chairman of the Board, effective immediately</font><font style="display: inline;font-family:Times;"> and</font><font style="display: inline;font-family:Times;"> Dr. </font><font style="display: inline;font-family:Times;">Michael Hunkapiller </font><font style="display: inline;font-family:Times;">will </font><font style="display: inline;font-family:Times;">continue to serve </font><font style="display: inline;font-family:Times;">as </font><font style="display: inline;font-family:Times;">President and Chief Executive of the Company</font><font style="display: inline;font-family:Times;">, as well as an active member of the board.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Previously, </font><font style="display: inline;">Dr. </font><font style="display: inline;">Michael Hunkapiller</font><font style="display: inline;"> held the </font><font style="display: inline;">combined </font><font style="display: inline;">role</font><font style="display: inline;">s</font><font style="display: inline;"> of </font><font style="display: inline;">Chairman,</font><font style="display: inline;"> President and Chief Executive Officer of Pacific Biosciences, and William Ericson, </font><font style="display: inline;">founding partner at Wildcat Venture Partners</font><font style="display: inline;">,</font><font style="display: inline;"> held the role of</font><font style="display: inline;"> Lead Independent Director of Pacific Biosciences</font><font style="display: inline;">.&nbsp;&nbsp;With the appointment of Christian Henry as the independent Chairman of the Board, Mr. Ericson will step down as Lead Independent Director, and</font><font style="display: inline;"> will </font><font style="display: inline;">also</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">continue to serve </font><font style="display: inline;">as a member</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of </font><font style="display: inline;">the </font><font style="display: inline;">company&#x2019;s </font><font style="display: inline;">board.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Henry</font><font style="display: inline;">, who </font><font style="display: inline;">has over 20 years of leadership experience</font><font style="display: inline;"> and was previously Executive Vice President and Chief Commercial Officer </font><font style="display: inline;">at</font><font style="display: inline;"> Illumina, </font><font style="display: inline;">joined </font><font style="display: inline;">the </font><font style="display: inline;">board </font><font style="display: inline;">in</font><font style="display: inline;"> July 2018 and has served on </font><font style="display: inline;">its </font><font style="display: inline;">Compensation Committee since June </font><font style="display: inline;">2019.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#x201C;Christian</font><font style="display: inline;">&#x2019;s </font><font style="display: inline;">deep </font><font style="display: inline;">domain</font><font style="display: inline;"> expertise</font><font style="display: inline;"> ha</font><font style="display: inline;">s</font><font style="display: inline;"> been a valuable addition to </font><font style="display: inline;">our Board,&#x201D; </font><font style="display: inline;">stated</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Dr.</font><font style="display: inline;"> Hunkapiller. &#x201C;</font><font style="display: inline;">Having an independent board chair is considered a corporate governance best practice, and Christian&#x2019;s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">experience </font><font style="display: inline;">at Illumina </font><font style="display: inline;">will </font><font style="display: inline;">serve him well in </font><font style="display: inline;">that role</font><font style="display: inline;">.&#x201D;</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#x201C;I am pleased </font><font style="display: inline;">and honored </font><font style="display: inline;">to </font><font style="display: inline;">take on</font><font style="display: inline;"> &nbsp;t</font><font style="display: inline;">he</font><font style="display: inline;"> role of Chair</font><font style="display: inline;">m</font><font style="display: inline;">an</font><font style="display: inline;">,&#x201D; said </font><font style="display: inline;">Mr.</font><font style="display: inline;"> Henry. &#x201C;I </font><font style="display: inline;">joined the Board because of my</font><font style="display: inline;"> enthusias</font><font style="display: inline;">m for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">PacBio&#x2019;s</font><font style="display: inline;"> truly unique SMRT Sequencing technology and </font><font style="display: inline;">commercial </font><font style="display: inline;">potential</font><font style="display: inline;">.&nbsp; </font><font style="display: inline;"> I look forward to </font><font style="display: inline;">continuing to </font><font style="display: inline;">work with the company&#x2019;s board and management team to drive </font><font style="display: inline;">even </font><font style="display: inline;">greater adoption </font><font style="display: inline;">of</font><font style="display: inline;"> PacBio&#x2019;s products</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in the global sequencing market</font><font style="display: inline;">.&#x201D;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">About Pacific Biosciences</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Pacific Biosciences of California, Inc.&nbsp;(NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT</font><font style="display: inline;font-size:6pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">) technology, Pacific Biosciences&#x2019; products enable:&nbsp;de novo&nbsp;genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length </font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#x2019; technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio</font><font style="display: inline;font-size:6pt;vertical-align:super;line-height:100%">&#xAE;</font><font style="display: inline;">&nbsp;sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available&nbsp;at&nbsp;</font><font style="display: inline;">www.pacb.com</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to </font><font style="display: inline;">commercialization or </font><font style="display: inline;">market adoption, </font><font style="display: inline;">availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, the suitability or utility of methods, products or technologies for particular applications or projects, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences&#x2019; control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences&#x2019; most recent filings with the&nbsp;Securities and Exchange Commission, including Pacific Biosciences&#x2019; most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption &#x201C;Risk Factors.&#x201D;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;">Contacts</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Media:&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Nicole Litchfield</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">415.793.6468</font><br /><font style="display: inline;"></font><font style="display: inline;">nicole@bioscribe.com</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Investors:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Trevin Rard</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">650.521.8450</font><br /><font style="display: inline;"></font><font style="display: inline;">ir@pacificbiosciences.com</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pacb-20200305xex99_1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pacb-20200305xex99_1g001.jpg
M_]C_X  02D9)1@ ! @$       #_[@ .061O8F4 9      !_]L 0P &! 0$
M!00&!04&"08%!@D+" 8&" L,"@H+"@H,$ P,# P,#! ,#@\0#PX,$Q,4%!,3
M'!L;&QP?'Q\?'Q\?'Q\?_]L 0P$'!P<-# T8$! 8&A41%1H?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?_\  $0@
M5 %H P$1  (1 0,1 ?_$ !P   (" P$!               '!08#! @" ?_$
M %@0  $# P(#! 4"#0X,!P    $" P0 !081$B$3!S%!(@A187$R%($5D4)2
M<H*R(S-SLQ88.+%B4V.#)(34=;4V%S=7H='"D],T=+0U585'DJ)#H\/$1O_$
M !L! 0 " P$!               ! @,%!@0'_\0 .A$!  (! @(%"@4!"0$
M      $" Q$$(04Q4=$2!D%Q@9&AL>$B<A/P8<$R-$+Q4F*"LB,S%!4D_]H
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M2?-':M./Y/C^0PQ,LL]J<QPW%L^))/<M!T6@^I0%3$O!N-KDPV[N2LUE)U+
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MU.O+2VT@:K6LA*0!WDG@*")C9GA\N2(L6^V]^43H&&I;"W"0=--J5DT$Q0%
M4!0% 4!0% 4&C<[[9+2A*[I<(T!"_=5*>;9![N!<*:#U;+U9KJT7;7/CSVD\
M%.1G4/)!]J"H4&Y0% 4!01UTR/'K2I*;K=(EO4OW!*?:9)U]',4GT4&>W76U
MW)CXBW3&)K'9S8[B'4:]OO(*A0;#CC;3:G'%!#: 5+6H@)2D#4DD]@%!I6J_
MV*[I<5:;E%N"6B ZJ*\V^$D]F[EJ5IK0<[>9RQJBY;;[ND:-7&+RU']MC*T5
M_P"1Q%8[NY\,9^]AM3RUM[)_$J%TO_M$QS^4&/MQ58Z6VYI_&R?3*\^8C'+^
MYG#ET:MTAVW+C,H3+;;4MK<@$*!4D$ ^VK6CBU7AW<XXP=R;1WM9X:\2TM>*
MY+=9"8]NM<J4ZH@:-M+(&OU2M-$CUDU71O,NZQ8XUM:(CSGM@'3VU=,;8]F>
M:/MMW-I"DQ(R%!?**TGP([G'UC5/AX :\>TB\1IQER?,.87WUXP8(^7RSU]E
M8(_,<JG9/DTV^RON;LES5IL'7E-H 2V@'A[J0./>>-4F=75;/:UP8HQQY/;U
MMI_I_P!1'%-K<L%S?YB$J;<3'>=!2H:I\:0H=_III+'7F&VCHO2/3$+AAGEZ
MR^[R6WKZW\RVL$%TN%)DK3WA#8W;3ZUZ:>@U,5:W>^(<..-,?SW]GK[$SU?Z
M@X_;L>:Z>X:I/P$<!NX2&2"C:@[N2E8]]2E^)Q7?V<=55-I\CS<GY?DODG<Y
M_P!T]$?KV?V%5AED7?<LM-I2G<)DIM#H''1K=JZK[% )JL.@WN?[6&U^J)^'
MM=QUF?*A0%!PAY=NB5@ZG_E!\[SY<+YH^#Y'PG+\?Q//W;^8A?9R!II0-Z=Y
M)<4$9:K7D=PCST^*.Z^AEQL+'$:I0EI7;Z%4'ORJ9QER[SD?3S))+DYS']YB
MONK+BVBP_P##O,[U>)2-Q!1K[O$=F@ 0> ?IDY'_  W\4B@G>OO5/,;EFD3I
M+T^<4S=YFQ%TG,J*7$EU._DI<'%I"&ONCJQQT]&AU#:L'DRP-F"%9%<Y]TNK
MHUD/LN)8:"U<24)*%K/'O6HZ^B@I6<=,LTZ"2FLUP&[R)F-I>0BZ0)1U"0HA
M*1)2WL;=;63MWA*5))&GIH'3>NM$(]"I74JS-@K,0%B.OQ<F8XZF+L<[-0T^
MOC]4!ZZ!.](.@4?JC8D]0>H-ZG7"1=G7?A66G4I44,.J:475J2L@;T*"4(VA
M(^@ ]=6?+BGI[9G,[Z=7>?$E6<AZ5&<=!<2T5 *6RZA+9T1KJI"]=4Z\>X@[
M>EW5%C(ND47-KTM+"HL9]5Y6D )2N%N#RPD=F]*-X3Z]*!#62TYWYD<EG7.Z
MW%ZR]/[:]RX\-KB-PT4EM"-=BWMA"G'5Z[=> TX4%^N7DQZ8OVXL0)USAS0D
M\N8MUMX;NXN-EM 4/4DI]M!7^AV;YKA/5"3T?S.6J>P=R;1*<45[%I;YS?+<
M5XBR\UV)5[JM -.-!I6#]-JY?NW\V)H(?J?A-OSCS9G%[@^[&AW!AOFOQ]O,
M3R+87T[=X4GBIH \.R@O'YDN _\ /;K]&-_HJ"U],O+3BG3_ "EO(K;=)\N4
MVRXP&9/)Y>UT:$^!"3J-/30<S]2KSD5@\P>2Y'8 OXVR3S,6M )2EH<MI?,
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M/H&H>DTF/,CU&;:2A7P+I2-"XM@A1]NQ:4_0%6[\M!;PWMIG^KUJ]D_5W/\
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M$LSG ZM?#]@E)\0[0CVB@ZRC2HTJ.W)BNH?C/)"V7VE!:%H4-0I*DZ@@CO%
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MH('J1Y9VLSSJ3E[63R;/+?0TVEN.P%*1RF@SJEP.MJ\0'&@@OS2+K_>/=?\
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,0% 4!0% 4!0%!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
